PFE Pfizer Inc. Company Overview $PFE
Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products. It also collaborates with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates through five operating segments: Primary Care, Specialty Care and Oncology, Established Products & Emerging Markets, Animal Health, and Consumer Healthcare. The Primary Care segment includes products in therapeutic and disease areas: Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. The Specialty Care and Oncology segment comprises the Specialty Care business unit and the Oncology business unit. The Specialty Care business unit includes products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. The Oncology business unit includes pharmaceutical products addressing oncology and oncology-related illnesses. The Established Products & Emerging Markets segment comprises the Established Products business unit and the Emerging Markets business unit. The Established Products unit includes pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. The Emerging Markets unit includes human prescription pharmaceutical products sold in emerging markets, including Asia, Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. The Animal Health & Consumer Healthcare segment comprises the Animal Health business unit and the Consumer Healthcare business unit. The Animal Health unit includes products and services to prevent and treat disease in livestock and companion animals, including vaccines, parasiticides and anti-infectives. The Consumer Healthcare segment includes non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. The company was founded by Charles Pfizer and Charles Erhart in 1849 and is headquartered in New York, NY.
PFE Last Price: 30.25
Last Updated: December 21, 2013 6:28 PM EST
PFE Stock Message Board and Forum http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Pfizer Inc. PFE Officers and Executives
Name Age Officer Since Title
Mr. Ian C. Read 59 - Chairman & Chief Executive Officer
Dr. Olivier Brandicourt 57 2007 President & General Manager-Emerging Markets
Mr. Frank A. D'Amelio 55 2007 Chief Financial Officer & EVP-Business Operations
Dr. Mikael Dolsten 54 2009 President-Worldwide Research & Development
Pfizer Inc.
235 East 42nd Street
New York, New York 10017-5755
Phone
1 2127332323
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$58.99B
Net Income
$9.49B
Employees
91,500
Annual Report Below for PFE
Pfizer Inc. PFE Recent Headlines
MarketWatch News on PFE
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Flush Coffers, Fat Payouts 2:34 a.m. Today - Barrons.com
Pfizer Inc's Buy Recommendation Affirmed 9:00 a.m. Dec. 20, 2013 - TheStreet.com
IPO Market Wraps Up Big Year 11:23 p.m. Dec. 19, 2013 - WSJ.com
'Dogs of the Dow' Strategy Should Be Muzzled 6:42 p.m. Dec. 19, 2013 - Barrons.com
Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus 5:37 p.m. Dec. 19, 2013 - Investors Business Daily
Pfizer’s Viagra Going Generic: Cheaper Options Coming Soon 5:26 p.m. Dec. 19, 2013 - Wall St. Cheat Sheet
Astra Buys Stake in Diabetes Venture 4:10 p.m. Dec. 19, 2013 - WSJ.com
5 Core Conservative Growth Stocks For A Retiree's Portfolio 3:36 p.m. Dec. 19, 2013 - Seeking Alpha
BlackBerry Future May Be Clearer With Earnings Report 1:10 p.m. Dec. 19, 2013 - Investors Business Daily
Stock Market News for December 19, 2013 - Market News 10:06 a.m. Dec. 19, 2013 - Zacks.com
Dow Today: Pfizer (PFE) Leads The Day Higher, UnitedHealth Group (UNH) Lags 10:00 a.m. Dec. 19, 2013 - TheStreet.com
Sanofi Pipeline Doesn't Support Price 6:00 a.m. Dec. 19, 2013 - TheStreet.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Dec. 18, 2013 - TheStreet.com
Top Five Guru-Held Health Care Stocks 4:42 p.m. Dec. 18, 2013 - GuruFocus.com
Elite Pharmaceuticals: Swinging For The Fences 10:53 a.m. Dec. 18, 2013 - Seeking Alpha
Novartis Answers Critics 6:30 a.m. Dec. 18, 2013 - TheStreet.com
Teva Secures Rights to Launch Generic Viagra 6:04 a.m. Dec. 18, 2013 - 247WallSt.com
Corporate Watch 11:28 p.m. Dec. 17, 2013 - WSJ.com
Recent Moves By Pfizer Management: No Big Deal Or Telegraphing A Sell-Off? 5:28 p.m. Dec. 17, 2013 - Seeking Alpha
Pfizer's Schulman to Leave Company 3:08 p.m. Dec. 17, 2013 - WSJ.com
Press Releases on PFE
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Patent Settlements, Stock Price Movements, and Financial Guidance - Research Report on Pfizer, Tenet, Rockwell Medical, Magellan Health Services, and HealthSouth 8:00 a.m. Dec. 20, 2013 - PR Newswire
FDA Accepts For Review ELIQUIS(R) (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE 5:01 p.m. Dec. 19, 2013 - BusinessWire
Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis 7:00 a.m. Dec. 19, 2013 - GlobeNewswire
Surgical Scar Market Is Ripe for Innovation 11:15 a.m. Dec. 18, 2013 - ACCESSWIRE
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
Teva Settles Viagra(R) Patent Litigation with Pfizer 4:35 p.m. Dec. 17, 2013 - BusinessWire
Pfizer Settles Viagra(R) Patent Litigation With Teva 11:55 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Invites Public To View And Listen To Webcast Of January 28 Conference Call With Analysts 10:00 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business 9:00 a.m. Dec. 17, 2013 - BusinessWire
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development 8:01 a.m. Dec. 17, 2013 - Marketwire
Pfizer Declares First-Quarter 2014 Dividend 11:20 a.m. Dec. 16, 2013 - BusinessWire
InvestorsObserver releases comments on Pfizer, Oracle, FedEx, Jabil Circuit, and Trulia 9:31 a.m. Dec. 16, 2013 - PR Newswire
Siemens Enters Into Master Agreement With Pfizer for Companion Diagnostics 9:26 a.m. Dec. 16, 2013 - BusinessWire
Critical Alerts For Pfizer, Halliburton, Joy Global, Anadarko Petroleum, and Hewlett Packard Released By InvestorsObserver 9:31 a.m. Dec. 12, 2013 - PR Newswire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 8:59 a.m. Dec. 11, 2013 - BusinessWire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 6:00 a.m. Dec. 11, 2013 - BusinessWire
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix 12:19 p.m. Dec. 10, 2013 - PR Newswire
New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line Results and Stock Price Movements - Research Report on Pfizer, Amgen, Puma Biotechnology, Abbott Laboratories, and Agilent 8:00 a.m. Dec. 10, 2013 - PR Newswire
Jason Hahn Named Chief Client Officer at WestLake Financial Group, Inc. 5:04 a.m. Dec. 10, 2013 - GlobeNewswire
Valuation
P/E Current
23.56
P/E Ratio (with extraordinary items)
5.65
P/E Ratio (without extraordinary items)
19.24
Price to Sales Ratio
3.16
Price to Book Ratio
2.25
Price to Cash Flow Ratio
11.04
Enterprise Value to EBITDA
7.56
Enterprise Value to Sales
3.71
Total Debt to Enterprise Value
0.19
Efficiency
Revenue/Employee
0.64
Income Per Employee
0.10
Receivables Turnover
4.53
Total Asset Turnover
0.32
Liquidity
Current Ratio
2.15
Quick Ratio
1.90
Cash Ratio
1.14
Profitability
Gross Margin
72.52
Operating Margin
32.15
Pretax Margin
20.48
Net Margin
16.09
Return on Assets
5.08
Return on Equity
11.61
Return on Total Capital
7.91
Return on Invested Capital
8.27
Capital Structure
Total Debt to Total Equity
46.12
Total Debt to Total Capital
31.55
Total Debt to Total Assets
20.16
Long-Term Debt to Equity
38.21
Long-Term Debt to Total Capital
26.14
Pfizer Inc. PFE Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 48.3B 50.01B 67.06B 65.26B 58.99B
Cost of Goods Sold (COGS) incl. D&A 10.04B 11.59B 20.71B 18.82B 16.21B
COGS excluding D&A 4.95B 6.83B 12.23B 9.91B 8.6B
Depreciation & Amortization Expense 5.09B 4.76B 8.49B 8.91B 7.61B
Depreciation 2.29B 1.76B 3.08B 3.36B 2.44B
Amortization of Intangibles 2.8B 3B 5.4B 5.54B 5.18B
Gross Income 38.26B 38.42B 46.34B 46.44B 42.78B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 21.64B 22.41B 28.61B 27.13B 23.81B
Research & Development 7.51B 7.75B 9.36B 8.4B 7.34B
Other SG&A 14.12B 14.66B 19.25B 18.73B 16.47B
Other Operating Expense 0 0 0 0 0
Unusual Expense 8.36B 5.96B 8.03B 6.23B 6.13B
EBIT after Unusual Expense (8.36B) (5.96B) (8.03B) (6.23B) (6.13B)
Non Operating Income/Expense 653M 787M 971M 445M 382M
Non-Operating Interest Income 1.29B 746M 402M 456M 383M
Equity in Affiliates (Pretax) 0 482M 0 0 0
Interest Expense 516M 1.23B 1.8B 1.68B 1.52B
Gross Interest Expense 562M 1.27B 1.83B 1.73B 1.57B
Interest Capitalized 46M 34M 36M 50M 41M
Pretax Income 9.69B 10.83B 9.28B 12.3B 12.08B
Income Tax 1.65B 2.2B 1.07B 3.91B 2.56B
Income Tax - Current Domestic 861M 10.24B (3.08B) 1.56B (796M)
Income Tax - Current Foreign 2.12B 1.54B 2.21B 2.05B 2.62B
Income Tax - Deferred Domestic (30M) (10.1B) 2B 124M 523M
Income Tax - Deferred Foreign (1.3B) 513M (67M) 183M 216M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 8.05B 8.63B 8.21B 8.4B 9.52B
Minority Interest Expense 23M 9M 31M 40M 28M
Net Income 8.03B 8.62B 8.18B 8.36B 9.49B
Extraordinaries & Discontinued Operations 78M 14M 77M 1.65B 5.08B
Extra Items & Gain/Loss Sale Of Assets 80M 0 (11M) 1.3B 4.78B
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (2M) 14M 88M 350M 297M
Net Income After Extraordinaries 8.1B 8.64B 8.26B 10.01B 14.57B
Preferred Dividends 3M 2M 2M 2M 2M
Net Income Available to Common 8.02B 8.62B 8.18B 8.35B 9.49B
EPS (Basic) 1.19 1.23 1.03 1.11 1.32
Basic Shares Outstanding 6.73B 7.01B 8.04B 7.82B 7.44B
EPS (Diluted) 1.19 1.23 1.02 1.11 1.30
Diluted Shares Outstanding 6.75B 7.05B 8.07B 7.87B 7.51B
EBITDA 21.72B 20.77B 26.22B 28.22B 26.58B
Pfizer Inc. PFE Filings
SEC Filings for Pfizer Inc.
Filing Date Document Date Type Category Amended
12/19/2013 12/16/2013 8-K Special Events
12/17/2013 12/16/2013 8-K Special Events
11/08/2013 09/29/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
09/30/2013 09/27/2013 8-K Special Events
09/27/2013 N/A SC 13G Institutional Ownership
08/09/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
06/03/2013 05/28/2013 8-K Special Events
05/29/2013 05/22/2013 8-K Special Events
05/10/2013 03/31/2013 10-Q Quarterly Reports
04/30/2013 04/30/2013 8-K Special Events
04/29/2013 04/25/2013 8-K Special Events
03/14/2013 04/25/2013 DEF 14A Proxy Statement
03/01/2013 12/31/2012 10-K/A Annual Reports *
02/28/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
01/29/2013 01/29/2013 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
SEC Filings provided by EDGAR Online, Inc.
PFE Pfizer Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products. It also collaborates with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates through five operating segments: Primary Care, Specialty Care and Oncology, Established Products & Emerging Markets, Animal Health, and Consumer Healthcare. The Primary Care segment includes products in therapeutic and disease areas: Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. The Specialty Care and Oncology segment comprises the Specialty Care business unit and the Oncology business unit. The Specialty Care business unit includes products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. The Oncology business unit includes pharmaceutical products addressing oncology and oncology-related illnesses. The Established Products & Emerging Markets segment comprises the Established Products business unit and the Emerging Markets business unit. The Established Products unit includes pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. The Emerging Markets unit includes human prescription pharmaceutical products sold in emerging markets, including Asia, Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. The Animal Health & Consumer Healthcare segment comprises the Animal Health business unit and the Consumer Healthcare business unit. The Animal Health unit includes products and services to prevent and treat disease in livestock and companion animals, including vaccines, parasiticides and anti-infectives. The Consumer Healthcare segment includes non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. The company was founded by Charles Pfizer and Charles Erhart in 1849 and is headquartered in New York, NY.
PFE Last Price: 30.25
Last Updated: December 21, 2013 6:28 PM EST
PFE Stock Message Board and Forum http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Pfizer Inc. PFE Officers and Executives
Name Age Officer Since Title
Mr. Ian C. Read 59 - Chairman & Chief Executive Officer
Dr. Olivier Brandicourt 57 2007 President & General Manager-Emerging Markets
Mr. Frank A. D'Amelio 55 2007 Chief Financial Officer & EVP-Business Operations
Dr. Mikael Dolsten 54 2009 President-Worldwide Research & Development
Pfizer Inc.
235 East 42nd Street
New York, New York 10017-5755
Phone
1 2127332323
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$58.99B
Net Income
$9.49B
Employees
91,500
Annual Report Below for PFE
Pfizer Inc. PFE Recent Headlines
MarketWatch News on PFE
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Flush Coffers, Fat Payouts 2:34 a.m. Today - Barrons.com
Pfizer Inc's Buy Recommendation Affirmed 9:00 a.m. Dec. 20, 2013 - TheStreet.com
IPO Market Wraps Up Big Year 11:23 p.m. Dec. 19, 2013 - WSJ.com
'Dogs of the Dow' Strategy Should Be Muzzled 6:42 p.m. Dec. 19, 2013 - Barrons.com
Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus 5:37 p.m. Dec. 19, 2013 - Investors Business Daily
Pfizer’s Viagra Going Generic: Cheaper Options Coming Soon 5:26 p.m. Dec. 19, 2013 - Wall St. Cheat Sheet
Astra Buys Stake in Diabetes Venture 4:10 p.m. Dec. 19, 2013 - WSJ.com
5 Core Conservative Growth Stocks For A Retiree's Portfolio 3:36 p.m. Dec. 19, 2013 - Seeking Alpha
BlackBerry Future May Be Clearer With Earnings Report 1:10 p.m. Dec. 19, 2013 - Investors Business Daily
Stock Market News for December 19, 2013 - Market News 10:06 a.m. Dec. 19, 2013 - Zacks.com
Dow Today: Pfizer (PFE) Leads The Day Higher, UnitedHealth Group (UNH) Lags 10:00 a.m. Dec. 19, 2013 - TheStreet.com
Sanofi Pipeline Doesn't Support Price 6:00 a.m. Dec. 19, 2013 - TheStreet.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Dec. 18, 2013 - TheStreet.com
Top Five Guru-Held Health Care Stocks 4:42 p.m. Dec. 18, 2013 - GuruFocus.com
Elite Pharmaceuticals: Swinging For The Fences 10:53 a.m. Dec. 18, 2013 - Seeking Alpha
Novartis Answers Critics 6:30 a.m. Dec. 18, 2013 - TheStreet.com
Teva Secures Rights to Launch Generic Viagra 6:04 a.m. Dec. 18, 2013 - 247WallSt.com
Corporate Watch 11:28 p.m. Dec. 17, 2013 - WSJ.com
Recent Moves By Pfizer Management: No Big Deal Or Telegraphing A Sell-Off? 5:28 p.m. Dec. 17, 2013 - Seeking Alpha
Pfizer's Schulman to Leave Company 3:08 p.m. Dec. 17, 2013 - WSJ.com
Press Releases on PFE
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Patent Settlements, Stock Price Movements, and Financial Guidance - Research Report on Pfizer, Tenet, Rockwell Medical, Magellan Health Services, and HealthSouth 8:00 a.m. Dec. 20, 2013 - PR Newswire
FDA Accepts For Review ELIQUIS(R) (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE 5:01 p.m. Dec. 19, 2013 - BusinessWire
Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis 7:00 a.m. Dec. 19, 2013 - GlobeNewswire
Surgical Scar Market Is Ripe for Innovation 11:15 a.m. Dec. 18, 2013 - ACCESSWIRE
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
Teva Settles Viagra(R) Patent Litigation with Pfizer 4:35 p.m. Dec. 17, 2013 - BusinessWire
Pfizer Settles Viagra(R) Patent Litigation With Teva 11:55 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Invites Public To View And Listen To Webcast Of January 28 Conference Call With Analysts 10:00 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business 9:00 a.m. Dec. 17, 2013 - BusinessWire
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development 8:01 a.m. Dec. 17, 2013 - Marketwire
Pfizer Declares First-Quarter 2014 Dividend 11:20 a.m. Dec. 16, 2013 - BusinessWire
InvestorsObserver releases comments on Pfizer, Oracle, FedEx, Jabil Circuit, and Trulia 9:31 a.m. Dec. 16, 2013 - PR Newswire
Siemens Enters Into Master Agreement With Pfizer for Companion Diagnostics 9:26 a.m. Dec. 16, 2013 - BusinessWire
Critical Alerts For Pfizer, Halliburton, Joy Global, Anadarko Petroleum, and Hewlett Packard Released By InvestorsObserver 9:31 a.m. Dec. 12, 2013 - PR Newswire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 8:59 a.m. Dec. 11, 2013 - BusinessWire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 6:00 a.m. Dec. 11, 2013 - BusinessWire
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix 12:19 p.m. Dec. 10, 2013 - PR Newswire
New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line Results and Stock Price Movements - Research Report on Pfizer, Amgen, Puma Biotechnology, Abbott Laboratories, and Agilent 8:00 a.m. Dec. 10, 2013 - PR Newswire
Jason Hahn Named Chief Client Officer at WestLake Financial Group, Inc. 5:04 a.m. Dec. 10, 2013 - GlobeNewswire
Valuation
P/E Current
23.56
P/E Ratio (with extraordinary items)
5.65
P/E Ratio (without extraordinary items)
19.24
Price to Sales Ratio
3.16
Price to Book Ratio
2.25
Price to Cash Flow Ratio
11.04
Enterprise Value to EBITDA
7.56
Enterprise Value to Sales
3.71
Total Debt to Enterprise Value
0.19
Efficiency
Revenue/Employee
0.64
Income Per Employee
0.10
Receivables Turnover
4.53
Total Asset Turnover
0.32
Liquidity
Current Ratio
2.15
Quick Ratio
1.90
Cash Ratio
1.14
Profitability
Gross Margin
72.52
Operating Margin
32.15
Pretax Margin
20.48
Net Margin
16.09
Return on Assets
5.08
Return on Equity
11.61
Return on Total Capital
7.91
Return on Invested Capital
8.27
Capital Structure
Total Debt to Total Equity
46.12
Total Debt to Total Capital
31.55
Total Debt to Total Assets
20.16
Long-Term Debt to Equity
38.21
Long-Term Debt to Total Capital
26.14
Pfizer Inc. PFE Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 48.3B 50.01B 67.06B 65.26B 58.99B
Cost of Goods Sold (COGS) incl. D&A 10.04B 11.59B 20.71B 18.82B 16.21B
COGS excluding D&A 4.95B 6.83B 12.23B 9.91B 8.6B
Depreciation & Amortization Expense 5.09B 4.76B 8.49B 8.91B 7.61B
Depreciation 2.29B 1.76B 3.08B 3.36B 2.44B
Amortization of Intangibles 2.8B 3B 5.4B 5.54B 5.18B
Gross Income 38.26B 38.42B 46.34B 46.44B 42.78B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 21.64B 22.41B 28.61B 27.13B 23.81B
Research & Development 7.51B 7.75B 9.36B 8.4B 7.34B
Other SG&A 14.12B 14.66B 19.25B 18.73B 16.47B
Other Operating Expense 0 0 0 0 0
Unusual Expense 8.36B 5.96B 8.03B 6.23B 6.13B
EBIT after Unusual Expense (8.36B) (5.96B) (8.03B) (6.23B) (6.13B)
Non Operating Income/Expense 653M 787M 971M 445M 382M
Non-Operating Interest Income 1.29B 746M 402M 456M 383M
Equity in Affiliates (Pretax) 0 482M 0 0 0
Interest Expense 516M 1.23B 1.8B 1.68B 1.52B
Gross Interest Expense 562M 1.27B 1.83B 1.73B 1.57B
Interest Capitalized 46M 34M 36M 50M 41M
Pretax Income 9.69B 10.83B 9.28B 12.3B 12.08B
Income Tax 1.65B 2.2B 1.07B 3.91B 2.56B
Income Tax - Current Domestic 861M 10.24B (3.08B) 1.56B (796M)
Income Tax - Current Foreign 2.12B 1.54B 2.21B 2.05B 2.62B
Income Tax - Deferred Domestic (30M) (10.1B) 2B 124M 523M
Income Tax - Deferred Foreign (1.3B) 513M (67M) 183M 216M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 8.05B 8.63B 8.21B 8.4B 9.52B
Minority Interest Expense 23M 9M 31M 40M 28M
Net Income 8.03B 8.62B 8.18B 8.36B 9.49B
Extraordinaries & Discontinued Operations 78M 14M 77M 1.65B 5.08B
Extra Items & Gain/Loss Sale Of Assets 80M 0 (11M) 1.3B 4.78B
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (2M) 14M 88M 350M 297M
Net Income After Extraordinaries 8.1B 8.64B 8.26B 10.01B 14.57B
Preferred Dividends 3M 2M 2M 2M 2M
Net Income Available to Common 8.02B 8.62B 8.18B 8.35B 9.49B
EPS (Basic) 1.19 1.23 1.03 1.11 1.32
Basic Shares Outstanding 6.73B 7.01B 8.04B 7.82B 7.44B
EPS (Diluted) 1.19 1.23 1.02 1.11 1.30
Diluted Shares Outstanding 6.75B 7.05B 8.07B 7.87B 7.51B
EBITDA 21.72B 20.77B 26.22B 28.22B 26.58B
Pfizer Inc. PFE Filings
SEC Filings for Pfizer Inc.
Filing Date Document Date Type Category Amended
12/19/2013 12/16/2013 8-K Special Events
12/17/2013 12/16/2013 8-K Special Events
11/08/2013 09/29/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
09/30/2013 09/27/2013 8-K Special Events
09/27/2013 N/A SC 13G Institutional Ownership
08/09/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
06/03/2013 05/28/2013 8-K Special Events
05/29/2013 05/22/2013 8-K Special Events
05/10/2013 03/31/2013 10-Q Quarterly Reports
04/30/2013 04/30/2013 8-K Special Events
04/29/2013 04/25/2013 8-K Special Events
03/14/2013 04/25/2013 DEF 14A Proxy Statement
03/01/2013 12/31/2012 10-K/A Annual Reports *
02/28/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
01/29/2013 01/29/2013 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
SEC Filings provided by EDGAR Online, Inc.
PFE Pfizer Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
